Pfizer, after discontinuing its initial danuglipron candidate due to safety concerns in April 2025, re-entered the race through a $10 billion acquisition of clinical-stage biotech Metsera in November 2025, securing a next-generation obesity pipeline [43]
In a double blinded randomised study, daily injections of semaglutide (0.4 mg) in obese patients resulted in an average of 14% decrease in body weight, over placebo, after a year
Use sterile handling techniques when preparing solutions
Fiber: Your Guts Best Friend Fruits, vegetables, legumes, and whole grains are not just good for your healththeyre fantastic for your GLP-1 levels too
Some patients may notice changes in appetite, meal size, blood sugar response, or weight over time
The design and protocol rationale were laid out in detail by Giblin et al